What You Should Know
- Global health technology leader ResMed has announced a definitive agreement to sell its MatrixCare business to healthcare-exclusive private equity firm Frazier Healthcare Partners for $450M.
- The corporate divestiture explicitly aligns with ResMed’s 2030 strategy, allowing the company to narrow its focus and reallocate capital toward high-growth, scalable opportunities in sleep health, breathing health, and cloud-connected home care.
- MatrixCare represents a major post-acute care platform, providing specialized enterprise software solutions to more than 15,000 providers across skilled nursing, senior living, life planning communities, home health, and hospice care settings.
- The transaction specifically includes MatrixCare and its affiliated software brands—including Healthcare First and Citus—while strictly excluding ResMed’s core U.S. DME billing platform, Brightree, and its European software business, MEDIFOX DAN.
- Backed by over $11 billion in total raised capital since inception, Frazier Healthcare Partners intends to invest aggressively in MatrixCare’s product innovation to capitalize on evolving post-acute clinical workloads.
Technical Segregation: Isolating the Institutional Portfolio
The boundaries of this transaction underscore a disciplined approach to asset rationalization. The sale encompasses the software solutions historically managed under the MatrixCare brand, including Healthcare First and Citus, alongside its native home health and hospice solutions. Collectively, this ecosystem supports more than 15,000 providers across skilled nursing, senior living, and life planning communities.
Crucially, ResMed is executing a strict separation of its digital health assets, excluding its high-performing home medical equipment (HME) and durable medical equipment (DME) software channels:
- Retention of Brightree: ResMed retains absolute ownership of Brightree in the United States, preserving its critical system of record that drives billing, inventory, and clinical workflows for DME suppliers.
- Retention of MEDIFOX DAN: The company keeps its dominant out-of-hospital software footprint in Germany, protecting its strategic operational anchor inside the European home care landscape.
- Frazier Capital Injection: Frazier Healthcare Partners—which has raised over $11 billion in capital and invested in more than 200 companies over its 35-year history—will take over 100% of the MatrixCare corporate entity, aggressively funding product innovation to streamline clinician workflows.
“Today’s announcement is about our disciplined approach to portfolio management and our commitment to driving long-term growth,” stated Mick Farrell, Chairman and CEO of ResMed. “By focusing on areas where we see the greatest opportunity for sleep health innovation and impact, we are strengthening our ability to deliver life-changing health technologies, improve patient outcomes and create value for our stakeholders.”
The 2030 Horizon: Fueling the Cloud-Connected Digital Front Door
The commercial rationale driving this transaction points directly to a broader industry shift toward continuous, automated home healthcare. As patients increasingly demand a “zero-distance” care experience that begins and ends in the household, the market value of home health technology is shifting from flat administrative recording toward active, AI-powered diagnostic and adherence orchestration.
By offloading the MatrixCare institutional platform, ResMed frees its capital allocation lines to double down on its cloud-connected hardware and software technologies. The company’s ecosystem functions as a continuous digital front door, leveraging embedded AI analytics within home respiratory devices to deliver highly personalized, near real-time sleep and breathing metrics.
By ensuring that its core technologies remain device-agnostic, interoperable, and traceably accurate, ResMed is positioned to capture a major share of the expanding value-based care market—equipping clinicians to proactively catch physiological shifts between standard office visits before they escalate into high-cost emergency room presentations.
